April 6th 2024
Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr. Peter Martin on Alternatives to Aggressive Therapy in Mantle Cell Lymphoma
February 5th 2016Peter Martin, MD, discusses the evolving paradigm of treatment for mantle cell lymphoma. Martin says the evolution of the paradigm currently includes Bruton's tyrosine kinase inhibitor, phosphoinositide 3-kinase inhibitor, immunomodulatory treatments, and immunotherapies.
Watch
Venetoclax Receives FDA Breakthrough Designation in AML
January 29th 2016The FDA has granted breakthrough therapy designation to Venetoclax combined with hypomethylating agents in patients with treatment-naive acute myeloid leukemia (AML) who are not eligible for standard high-dose induction treatment, according to AbbVie, which is codeveloping the BCL-2 inhibitor with Genentech.
Read More
Researchers Analyze Karyotype Complexity and Prognosis in Acute Myeloid Leukemia
January 29th 2016Diagnosis of acute myeloid leukemia (AML) is pivoted around cytogenetic analysis of patient bone marrow or peripheral blood cultures. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues is based on cytogenetic features along with other clinical, morphological, and immunophenotypic characteristics.
Read More
Dr. Anthony Mato on the Difference Between Intolerance and Resistance in CLL
January 22nd 2016Anthony Mato, MD, MSCE, director of the CLL Program, University of Pennsylvania, discusses the difference between intolerance and resistance when giving patients with chronic lymphotic leukemia ibrutinib.
Watch
Carfilzomib Combo Approved by FDA for Relapsed Multiple Myeloma
January 22nd 2016Carfilzomib (Kyprolis) has been approved by the FDA in combination with either dexamethasone or lenalidomide plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with 1 to 3 lines of therapy. The approval is based on findings from the phase III ENDEAVOR trial.
Read More
Dr. John McCarty on Advice for Patients With Lymphoma Seeking Stem Cell Mobilization
January 22nd 2016​John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.
Watch
Venetoclax/Rituximab Combo Gains FDA Breakthrough Designation in CLL
January 21st 2016The FDA has designated the BCL-2 inhibitor venetoclax as a breakthrough therapy for use in combination with rituximab (Rituxan) to treat patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
FDA Approves Ofatumumab for Elongated Treatment of Patients With CLL
January 19th 2016Ofatumumab (Arzerra) has received FDA approved for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia (CLL). Patients eligible to receive the treatment must show complete or partial response following at least two lines of therapy.
Read More
Post-Study Paradigm Shift in CML Highlights Need for Accurate Molecular Monitoring
January 14th 2016A new retrospective study claimed a rarity of cytogenetic and molecular monitoring exists among patients with chronic myelogenous leukemia (CML) treated in a community setting; however, one researcher is challenging that claim.
Read More
FDA Issues Venetoclax Priority Review as Second-Line Treatment in CLL
January 12th 2016Venetoclax has been granted priority review status by the FDA for use in adults with chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. This patient population includes those with a 17p deletion (del[17p]), according to codevelopers of the BCL-2 inhibitor AbbVie and Genentech.
Read More
Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.
Watch
Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma
January 6th 2016Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
Watch
Triplets in Newly Diagnosed Multiple Myeloma: A Q&A With S. Vincent Rajkumar, MD
December 18th 2015With numerous newly approved drugs for patients with early-stage multiple myeloma reaching the clinics, understanding what drugs, combinations, and sequences to use has become an important area of research. Several recent studies have demonstrated increased efficacy with nominally increased adverse events in these triplet arms.
Read More
Pregnancy Disproved as Potential Trigger for Relapse in Hodgkin Lymphoma Survivors
December 17th 2015Researchers discovered that pregnancy while in remission of Hodgkin lymphoma does not increase the risk of cancer relapse, making this report the first largest study to specifically examine the impacts of pregnancy as a potential trigger for relapse in Hodgkin lymphoma survivors.
Read More
Study Demonstrates Tolerability of Obinutuzumab Combo in Patients with Previously Untreated CLL
December 10th 2015A combination of venetoclax and obinutuzumab, followed by additional cycles of venetoclax, has shown tolerability in elderly patients with previously untreated chronic lymphocytic leukemia with comorbidities, data from the CLL14 trial (BO25323) shows.
Read More
Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
December 10th 2015Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Watch
Pembrolizumab Combo Elicits Response Rate of Over 75% in Refractory Myeloma
December 10th 2015The PD-1 inhibitor pembrolizumab in combination with an established multiple myeloma regimen showed responses in 76% of a cohort of 17 patients with relapsed/refractory disease in data one of several clinical trials presented at the 2015 ASH Annual Meeting.
Read More
Blinatumomab Displays Impressive CR Rates in ALL Studies
December 10th 2015Blinatumomab (Blincyto) as a single agent showed high complete remission (CR), or CR with partial hematological recovery, in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.
Read More
FDA Approves Rapid Infusion Bendamustine for CLL and NHL
December 10th 2015A rapid infusion formulation of bendamustine (Bendeka) has received FDA approval for the treatment of patients with CLL or indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.
Read More
Dr. David Steensma on Midostaurin and its Future Uses in Acute Leukemia
December 8th 2015David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Watch
Response Rates Hover Around 100% for CAR T-cell Therapies in ALL
December 8th 2015Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.
Read More